Literature DB >> 15929036

Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation.

Hao Deng, Weidong Le, Yi Guo, Christine B Hunter, Wenjie Xie, Joseph Jankovic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15929036     DOI： 10.1002/ana.20510

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  19 in total

Review 1.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

2.  The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.

Authors:  Jason P Covy; Benoit I Giasson
Journal:  J Neurochem       Date:  2010-08-19       Impact factor: 5.372

Review 3.  α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.

Authors:  Jason P Covy; Benoit I Giasson
Journal:  Neurotoxicology       Date:  2011-01-14       Impact factor: 4.294

Review 4.  Epigenetic mechanisms of neurodegenerative diseases and acute brain injury.

Authors:  Mario J Bertogliat; Kahlilia C Morris-Blanco; Raghu Vemuganti
Journal:  Neurochem Int       Date:  2019-12-12       Impact factor: 3.921

5.  Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy.

Authors:  Yu-Chin Su; Xing Guo; Xin Qi
Journal:  Biochim Biophys Acta       Date:  2014-11-15

6.  Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.

Authors:  Wanli W Smith; Zhong Pei; Haibing Jiang; Darren J Moore; Yideng Liang; Andrew B West; Valina L Dawson; Ted M Dawson; Christopher A Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

7.  Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.

Authors:  Min Liu; Samantha A Bender; Gregory D Cuny; Woody Sherman; Marcie Glicksman; Soumya S Ray
Journal:  Biochemistry       Date:  2013-03-01       Impact factor: 3.162

Review 8.  Targets for neuroprotection in Parkinson's disease.

Authors:  Talene A Yacoubian; David G Standaert
Journal:  Biochim Biophys Acta       Date:  2008-10-01

9.  Testing association between LRRK2 and Parkinson's disease and investigating linkage disequilibrium.

Authors:  C Paisán-Ruíz; E W Evans; S Jain; G Xiromerisiou; J R Gibbs; J Eerola; V Gourbali; O Hellström; J Duckworth; A Papadimitriou; P J Tienari; G M Hadjigeorgiou; A B Singleton
Journal:  J Med Genet       Date:  2006-02       Impact factor: 6.318

10.  Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2.

Authors:  Jason P Covy; Benoit I Giasson
Journal:  Biochem Biophys Res Commun       Date:  2008-11-21       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.